Status:
NOT_YET_RECRUITING
The Value of 68Ga-FAPI PET/CT for Evaluating Peritoneal Treatment Response
Lead Sponsor:
Erasmus Medical Center
Conditions:
Peritoneal Metastasis
FAPI
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Peritoneal metastases (PM), commonly originating from gastrointestinal and ovarian cancers, are associated with a poor prognosis and limited treatment options due to the diffuse nature of the disease ...
Eligibility Criteria
Inclusion
- A planned start of repeated IP chemotherapy (with or without the combination of systemic chemotherapy) for macroscopic peritoneal metastases;
- WHO-performance score of 0 to 1;
- Aged 18 years or older;
- Written informed consent according to the ICH-GCP and national/local regulations.
Exclusion
- Impaired renal function, defined as eGFR \<25 ml/min/1,73 m2. An exception can be made in consultation with the treating physician;
- Pregnancy/breastfeeding. For the latter, temporary discontinuation may be considered;
- Known allergic reaction to therapeutic radiopharmaceuticals;
- Inability to lie still on the back for the duration of PET-CT;
- Any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient's experience of study burden (such as non-suppressible claustrophobia).
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06957782
Start Date
September 1 2025
End Date
March 1 2027
Last Update
May 9 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.